Peptide Market Trend: What’s Driving Glucagon Demand in 2024?
Published: 15 7 月, 2026 16:33
Author: Kathleen Dennis
Abstract: Driven by rising diabetes and obesity prevalence, glucagon demand in 2024 is surging, particularly for dual-action GLP-1/GIP agonists and rescue pen formulations. Market analysis reveals a 12.3% CAGR for peptide therapeutics, with Novo Nordisk and Eli Lilly dominating through superior purity (>99%) and stability profiles. Key differentiators include lyophilized vs. liquid formulations, where liquid offers convenience but requires cold-chain logistics (2-8°C). Regulatory compliance (FDA/EMA) and GMP-certified manufacturing remain critical for efficacy and safety. Selecting high-purity, endotoxin-tested peptides from validated suppliers ensures optimal therapeutic outcomes.